Casdin Capital TNYA Position
ActiveCasdin Capital held their position in Tenaya Therapeutics, Inc. (TNYA) in Q4 2025, holding $258K worth of shares across 361,969 shares.
The position was first reported in Q1 2023 and has been tracked across 12 quarterly 13F filings.
1 other tracked fund also holds TNYA.
There is an upcoming Phase 2 readout in 502 days (Aug 31, 2027), making the timing of Casdin's position particularly relevant.
Short interest stands at 22.3% of float with 4.2 days to cover, indicating significant bearish positioning against Casdin's long thesis.
About Tenaya Therapeutics, Inc.
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
Full company profile →Short Interest
22.3%
4.2 days to cover
Casdin Capital TNYA Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Held | 361,969 | — | $258K |
| Q3 2025 | Held | 361,969 | — | $586K |
| Q2 2025 | Decreased | 361,969 | -6,371,002 | $221K |
| Q1 2025 | Held | 6,732,971 | — | $3.8M |
| Q4 2024 | Held | 6,732,971 | — | $9.6M |
| Q3 2024 | Held | 6,732,971 | — | $13.0M |
| Q2 2024 | Held | 6,732,971 | — | $20.9M |
| Q1 2024 | Increased | 6,732,971 | +351,594 | $35.2M |
| Q4 2023 | Held | 6,381,377 | — | $20.7M |
| Q3 2023 | Held | 6,381,377 | — | $16.3M |
| Q2 2023 | Increased | 6,381,377 | +302,517 | $37.5M |
| Q1 2023 | New | 6,078,860 | +6,078,860 | $17.3M |
Frequently Asked Questions
Does Casdin Capital own TNYA?
Yes. As of Q4 2025, Casdin Capital holds 361,969 shares of Tenaya Therapeutics, Inc. (TNYA) valued at $258K. This data comes from their SEC 13F filing.
How many hedge funds own TNYA?
2 specialist biotech hedge funds currently hold TNYA, including RA Capital Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Casdin Capital first buy TNYA?
Casdin Capital's position in TNYA was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Casdin Capital's TNYA position increasing or decreasing?
Casdin Capital held their TNYA position unchanged in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
TNYACompany Page →
All fund holders, insider trades, catalysts, and cash runway
Casdin CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →